Literature DB >> 31733724

Membranous Lupus Nephritis: A Clinical Review.

Salem Almaani1, Samir V Parikh2.   

Abstract

Membranous lupus nephritis (MLN) (Class V lupus nephritis [LN]) is a distinct form of LN defined by the presence of subepithelial immune complex deposits seen on kidney biopsy. MLN is often associated with the nephrotic syndrome. The histology of MLN closely resembles that of idiopathic (primary) membranous nephropathy (pMN). However, MLN typically has abundant mesangial deposits that are absent in primary membranous nephropathy. The clinical presentation, management, and prognosis of MLN differ from that of the proliferative forms of LN (Class III, IV, or Mixed III/IV + V). Although immunosuppressive therapy is often warranted in MLN, the optimal treatment regimen remains unclear. Here we describe the clinical presentation, histologic features, and natural history of MLN. We also review the role of supportive treatment and discuss when to deploy immunosuppressive management in MLN.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Class V lupus nephritis; Lupus nephritis; Membranous lupus nephritis; Systemic lupus erythematosus

Year:  2019        PMID: 31733724     DOI: 10.1053/j.ackd.2019.08.009

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  6 in total

Review 1.  Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.

Authors:  Xiao-Ying Quan; Hao-Tao Chen; Si-Qin Liang; Chen Yang; Cui-Wei Yao; Yong-Zhi Xu; Hua-Feng Liu; Ning An
Journal:  Biomed Res Int       Date:  2022-05-26       Impact factor: 3.246

2.  Diffusion tensor imaging of renal cortex in lupus nephritis.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Mohamed Abdel Khalek; Samar Tharwat; Mohammed Kamal Nassar; Nihal Tharwat
Journal:  Jpn J Radiol       Date:  2021-06-14       Impact factor: 2.374

3.  Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans.

Authors:  Bingileki F Lwezaula; Oluwatoyin I Ameh; Udeme E Ekrikpo; Francois Cj Botha; Ugochi S Okpechi-Samuel; Nicola Wearne; Pierre Ronco; Aminu K Bello; Ikechi G Okpechi
Journal:  BMC Nephrol       Date:  2021-01-07       Impact factor: 2.388

4.  Anti-DFS70 Antibodies Are Associated With Proliferative Lupus Nephritis and Renal Pathological Activity.

Authors:  Dandan Chen; Li Zhao; Yingxin Dai; Fang Du; Enling Li; Xiangyu Niu; Zhiqing Wang; Bing Zheng; Liangjing Lu
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

5.  MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study.

Authors:  Min Wang; Li Huang; Liping Peng; Yameng Yang; Jing Mao; Ning Zhu; Bin Wu
Journal:  Ann Transl Med       Date:  2022-08

6.  Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov.

Authors:  Yanfang Gao; Yuhan Wang; Rongshan Li; Xiaoshuang Zhou
Journal:  Front Med (Lausanne)       Date:  2021-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.